Employing CETSA® in Primary Screening for p53 Binders

Revolutionizing p53 Binder Screening: Uncovering Potential Cancer Therapeutics with CETSA Targeting p53, a protein often considered “undruggable” in cancer research, remains a challenging but essential task in developing novel cancer therapies. Our study utilizes CETSA (Cellular Thermal Shift Assay) to screen for p53 binders in intact SK-BR-3 breast cancer cells. This approach not only identifies compounds that bind to p53 but also reveals those that stabilize its activity, offering new opportunities for cancer treatment. By focusing on compounds active in live cells, CETSA improves upon traditional high-throughput screening (HTS) methods, which often fail to reflect true cellular biology. This innovative method allows for rapid hit generation, efficiently identifying potential lead compou...